KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 58,620,381
- Share change
- +4,149,716
- Total reported value
- $714,026,876
- Put/Call ratio
- 75%
- Price per share
- $12.18
- Number of holders
- 143
- Value change
- +$51,785,657
- Number of buys
- 77
- Number of sells
- 62
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
13%
|
6,728,985
|
$76,071,175 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
9.9%
|
4,941,798
|
$63,650,358 | $0 | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.8%
|
4,955,000
|
$56,016,275 | — | 30 Jun 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
9.7%
|
4,887,867
|
$55,257,336 | — | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13F
13D/G
|
Company |
1.5%
from 13D/G
|
4,675,000
|
$52,850,875 | — | 30 Jun 2025 | |
| Capital World Investors |
13D/G
13F
|
Company |
6.4%
|
3,177,587
|
$40,927,321 | $0 | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.2%
|
3,129,494
|
$35,378,930 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.8%
|
2,412,399
|
$27,272,171 | — | 30 Jun 2025 | |
| Woodline Partners LP |
13F
|
Company |
3.8%
|
1,920,664
|
$21,713,107 | — | 30 Jun 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.6%
|
1,832,171
|
$20,712,693 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
1,349,539
|
$15,256,538 | — | 30 Jun 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2.5%
|
1,273,333
|
$14,395,030 | — | 30 Jun 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
2.1%
|
1,038,049
|
$11,735,144 | — | 30 Jun 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
1.9%
|
945,125
|
$10,684,639 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
941,212
|
$10,642,376 | — | 30 Jun 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
1.5%
|
768,972
|
$8,693,228 | — | 30 Jun 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.3%
|
679,063
|
$7,676,807 | — | 30 Jun 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
1.2%
|
581,757
|
$6,576,763 | — | 30 Jun 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
1.1%
|
554,958
|
$6,273,800 | — | 30 Jun 2025 | |
| Thomas Andrew Crockett |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
322,315
mixed-class rows
|
$4,648,801 | — | 17 Feb 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.76%
|
386,790
|
$4,372,661 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.73%
|
366,966
|
$4,148,551 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.7%
|
352,152
|
$3,981,078 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.67%
|
340,629
|
$3,850,811 | — | 30 Jun 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.64%
|
323,170
|
$3,653,437 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.59%
|
299,194
|
$3,382,388 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.58%
|
294,198
|
$3,325,908 | — | 30 Jun 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.58%
|
292,593
|
$3,307,764 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.54%
|
272,861
|
$3,084,694 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.47%
|
239,629
|
$2,709,011 | — | 30 Jun 2025 | |
| First Turn Management, LLC |
13F
|
Company |
0.42%
|
214,138
|
$2,420,830 | — | 30 Jun 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.39%
|
198,528
|
$2,244,360 | — | 30 Jun 2025 | |
| F/m Investments LLC |
13F
|
Company |
0.36%
|
182,262
|
$2,060,472 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.34%
|
173,209
|
$1,958,552 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.33%
|
168,923
|
$1,909,675 | — | 30 Jun 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.31%
|
157,725
|
$1,783,081 | — | 30 Jun 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.31%
|
155,961
|
$1,763,139 | — | 30 Jun 2025 | |
| NAN FUNG TRINITY (HK) Ltd |
13F
|
Company |
0.31%
|
154,522
|
$1,746,871 | — | 30 Jun 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.29%
|
148,927
|
$1,683,620 | — | 30 Jun 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.29%
|
145,282
|
$1,642,409 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.27%
|
134,398
|
$1,519,369 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.26%
|
133,566
|
$1,509,960 | — | 30 Jun 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.26%
|
132,900
|
$1,502,434 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.24%
|
119,622
|
$1,351,730 | — | 30 Jun 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.22%
|
113,496
|
$1,283,072 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.21%
|
107,635
|
$1,216,814 | — | 30 Jun 2025 | |
| Edward P. Feener |
3/4/5
|
CHIEF SCIENTIFIC OFFICER |
—
mixed-class rows
|
102,024
mixed-class rows
|
$1,200,262 | — | 17 May 2024 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.2%
|
101,035
|
$1,142,203 | — | 30 Jun 2025 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
0.2%
|
100,000
|
$1,130,500 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.19%
|
97,248
|
$1,099,389 | — | 30 Jun 2025 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q3 2025
As of 30 Sep 2025,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
143 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,620,381 shares.
The largest 10 holders included
VR ADVISER, LLC, TANG CAPITAL MANAGEMENT LLC, Frazier Life Sciences Management, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, Capital World Investors, BlackRock, Inc., VANGUARD GROUP INC, MILLENNIUM MANAGEMENT LLC, Woodline Partners LP, and GOLDMAN SACHS GROUP INC.
This page lists
143
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
138
Q3 2025 holders
143
Holder diff
5
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.